Best Healthcare Investment Banks and M&A Firms by Fit (2026)

Best healthcare investment banks and M&A firms at a glance

Sixteen firms appear in this guide. They are grouped by use case (healthcare services and the lower middle market, healthcare IT and digital health, and medtech, diagnostics, and life sciences) and listed alphabetically within each group. The table is not a ranking; the right column shows one verified, dated credential per firm with its source date. Windsor Drake, the publisher, appears first as a disclosed featured profile, outside the alphabetical grouping.

"Not publicly disclosed" means the firm does not publish engagement minimums or deal-size ranges; treat any third-party estimate of those figures with skepticism. Each firm name links to the official practice or transaction source used for its row.

How we evaluated the firms

This guide is a comparison framework, not a league table, and it does not use a composite score. Firms were included when public evidence supports four things: verified current healthcare transactions or mandates; healthcare-only focus or a clearly defined subsector specialization; relevance to sell-side work at an identifiable company or deal scale; and demonstrated senior-team depth. Where independent recognition exists, such as LSEG's 2025 healthcare M&A rankings as published by Houlihan Lokey, or Axial's 2025 Top 50 lower-middle-market healthcare list (published September 18, 2025), it is cited beside the specific claim it supports and nowhere else.

The source hierarchy runs in one direction: official firm disclosures first (practice pages, transaction announcements, team pages), independent league tables and marketplace data second, and current primary market research (Bain, PwC) for market context only. Every credential in this guide carries a date: either the transaction date or the date we accessed the source. Where a firm does not publish deal-size ranges, fee levels, or deal counts, the guide says "Not publicly disclosed" rather than estimating. Research date: August 20, 2026. Scope: US sell-side healthcare M&A. Exclusions: business brokers without documented healthcare transactions, firms with no verifiable current healthcare activity, and accounting-led corporate finance teams.

Conflict and corrections. Windsor Drake publishes this guide and competes for healthcare technology and tech-enabled-services mandates; its profile is a disclosed publisher feature shown first, outside the alphabetical listings, and inclusion cannot be bought: no firm paid to appear, and no listing is conditioned on a link or referral. Firms named here can submit updated primary sources or corrections through the firm's contact page; substantive changes are logged against the methodology version above.

Best healthcare-services M&A advisors

These firms concentrate on healthcare services and the lower middle market: behavioral health, ABA, and addiction treatment; physician and dental groups, including MSO structures; home health, hospice, and DME; post-acute and senior care; and tech-enabled services. What separates them from generalist banks is buyer coverage, meaning live relationships with the consolidators, sponsors, and platforms actually paying premiums in each subsector, and pattern recognition on reimbursement, licensure, and physician-alignment diligence. Firms are listed alphabetically.

Best healthcare IT and digital-health investment banks

Healthcare IT (HCIT) and digital health are a different market from healthcare services. The buyers are strategics, vertical-software consolidators, and technology-focused sponsors; the valuation grammar is recurring revenue, net retention, and EHR integration depth rather than clinic-level EBITDA. The firms below have current, verifiable deal activity across HCIT and digital health: revenue-cycle management, clinical workflow, payer and employer technology, interoperability, data and analytics, AI-enabled healthcare, pharmacy IT, population health, healthcare cybersecurity, and tech-enabled services. Windsor Drake, the publisher of this guide, appears first as a disclosed publisher profile; the remaining firms are listed alphabetically.

Best medtech, diagnostics, and life-sciences banks

Pre-revenue biopharma, medical devices, diagnostics, and profitable healthcare services are four different transactions wearing the same industry label. Biopharma sells science: value turns on clinical data, regulatory pathway, and pipeline optionality, and the advisor needs licensing and capital-markets fluency alongside M&A. Devices and diagnostics sell regulated products: reimbursement codes, FDA clearance history, and strategic-acquirer whitespace drive value. Profitable services and software sell cash flow and retention. No single advisor type is best for all four; the banks below earn their place in science- and device-driven mandates specifically. Firms are listed alphabetically.

Where the bulge brackets fit

For healthcare transactions at global-platform scale (multi-billion-dollar carve-outs, cross-border take-privates, contested situations), the largest banks field healthcare groups with balance sheets and geographic reach no specialist can replicate: Evercore, Goldman Sachs (third in LSEG's 2025 global healthcare count, at 41 deals, per the table above), J.P. Morgan, and Morgan Stanley (fifth, at 32). For a founder-led company in the lower middle market, they are rarely the right call, not because they lack skill but because mandate economics put junior teams on smaller deals. Match the platform to the transaction, not to the letterhead.

Best lower-middle-market healthcare M&A firms by seller type

Lower-middle-market healthcare sellers get the best outcomes from advisors already trading their exact business model. Use the table below to build a starting shortlist by seller type, then apply the diligence checklist. This is a shortlist for further diligence, not a guaranteed ranking; firm fit still depends on your size, geography, and timing.

Specialist healthcare bank vs boutique vs bulge bracket

Advisor type predicts the experience of the process: who does the work, how buyers are approached, and where your mandate ranks in the firm's priorities. The comparison below is qualitative by design: published engagement minimums are rare, and invented cutoffs are worse than none.

How to choose a healthcare M&A advisor

Choose the advisor who has closed transactions in your exact subsector within the last 24 months, will commit a named senior banker to daily execution, can defend a valuation range with current evidence, and offers reference calls with comparable founders. Subsector fit and senior attention predict outcomes better than brand size.

Put every candidate firm through the same ten questions, in writing where possible. Strong firms answer all ten without hedging; weak fits reveal themselves by question four.

1. Which transactions in my exact subsector have you closed in the last 24 months?
2. Who were the seller, the buyer, and the day-to-day transaction team on each?
3. Which senior banker will run daily execution on my mandate?
4. Which buyers are most likely to pay a premium for my company, and why?
5. What reimbursement, billing, compliance, data-security, or physician-alignment issue will buyers challenge in diligence?
6. How will you defend value through quality-of-earnings and confirmatory diligence?
7. Would you recommend a broad auction, a controlled auction, or a targeted process, and why?
8. What verifiable valuation evidence supports the range you are quoting me?
9. What are the retainer, minimum fee, success fee, tail, and expense terms?
10. May I speak with three directly comparable founder references?

On question eight, insist on current, published evidence rather than a verbal "market is strong." Current subsector benchmarks, for example quarterly healthcare software valuation data of the kind compiled in dated, methodology-disclosed research reports, let you test whether an advisor's range is analysis or salesmanship. The process design question matters just as much: how Windsor Drake runs a sale is published start to finish, and any firm you shortlist should be willing to walk you through its equivalent at the same level of detail.

What healthcare M&A advisors charge

Most sell-side healthcare M&A advisors charge a retainer plus a success fee calculated on transaction value at closing, often with a minimum fee, a tail period, and expense reimbursement. Exact levels vary with transaction size and complexity and are negotiated per engagement; no reliable industry-standard percentage exists in public sources.

The components work together. The retainer, monthly or staged, compensates preparation work and filters unserious processes; it is often credited against the success fee. The success fee is the advisor's real economics, typically structured as a percentage of transaction value, sometimes with breakpoints or an incentive kicker above a target price. A minimum fee protects the advisor on smaller outcomes. The tail entitles the advisor to a fee if you close with an introduced buyer within a defined period after termination; negotiate its length and buyer-list scope carefully. Expenses are usually reimbursed with a cap.

Treat any published "standard percentage" with suspicion: fee levels move with deal size, competitive tension among advisors, and complexity, and firms do not disclose them. What you can do is compare structures on identical terms across two or three finalists. Windsor Drake publishes its fees and engagement model in full; ask every firm on your shortlist to do the same before you sign.

2026 healthcare M&A market context

The 2026 backdrop favors prepared sellers. Bain's Global Healthcare Private Equity Report 2026 reports that healthcare private equity reached a record high in global deal value in 2025, with deal count posting the second-highest annual total on record and strength across all deal sizes; Bain also flags the return of sponsor-to-sponsor activity and the growing importance of AI and operational sophistication in underwriting.

Within US health services, PwC's US Deals 2026 midyear outlook (June 17, 2026) reports that physician medical groups captured 46% of first-quarter 2026 deal volume with deal count up 18% year over year, while eHealth captured 61% of disclosed first-quarter deal value despite a 29% decline in deal count: fewer, larger technology deals. PwC also notes that AI capability has shifted from a valuation story to a diligence requirement: buyers now underwrite demonstrated operating impact, not pilot-stage promise.

Two implications for sellers choosing an advisor. First, buyer selectivity is up (PwC describes acquirers prioritizing scalable, cash-generating platforms with clear reimbursement visibility), so advisor preparation on payer mix, labor model, and compliance exposure now moves price, not just probability of close. Second, with volume concentrated in physician groups and value concentrated in eHealth, subsector-matched advisors are seeing the freshest comparable evidence. The advisor who traded three businesses like yours this year knows what buyers are actually paying this quarter; that currency is precisely what this guide's verified-evidence standard is designed to surface.